Ring Therapeutics, a Cambridge, MA-based life sciences company focused on advancing a gene therapy, raised $86.5M in Series C funding.
The round, which brought total funds raised to date to $230M, was led by Alexandria Venture Investments, Altitude Life Science Ventures, CJ Investment, Ring’s founder Flagship Pioneering, Invus, Kyowa Kirin Co., Partners Investment, funds and accounts advised by T. Rowe Price Associates, Inc., and UPMC Enterprises.
Founded in 2017 by Flagship Pioneering, and led by Tuyen Ong, MD, MBA, Chief Executive Officer (and CEO-Partner at Flagship Pioneering) and Co-Founder and Chairman Avak Kahvejian, Ph.D. (General Partner at Flagship Pioneering), Ring Therapeutics is focused on advancing gene therapy and the nucleic acid medicine space by harnessing the abundant and diverse member of the human commensal virome, anelloviruses. To this end, the company developed the Anellogy platform, which focuses on anelloviruses to potentially treat a broad range of diseases. Through harnessing the properties of these commensal viruses, the platform generates diverse vectors that exhibit both tissue-specific tropism and the potential to be re-dosed.
The company intends to use the funds to expand operations and its development efforts to further advance its Anellogy™ platform toward the clinic, transforming commensal anelloviruses into life-saving therapies.
FinSMEs
09/03/2023